With the availability of this remarkable tool, it's hard to understand why so many researchers continue to use grain - based chow diets in nutrition studies and even, as we shall see, in studies that are not necessarily nutrition - oriented, such as drug and
compound efficacy studies, or behavioral studies.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational
compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and
efficacy data from clinical
studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Apart from patient testimonials and a few preliminary
studies in tumor cell lines and in mice, critics say, there is no evidence of the safety or
efficacy of the
compound, popularly known as the «cancer pill» or «fosfo.»
I mean, if there is existing literature
studies looking at those plants where they found active
compound [s], I definitely will use that, but first I am trying to show that there is a pattern — that if you do some math and try to synthesize all this information about the different plants being used in different cultures for different diseases, and using the evolutionary relationships of the plants, the cultures and the diseases to sort of merge it all together and have these equations spit out a sort of potential
efficacy — our best guess of what the
efficacy of this plant is.
«We are exploring alternative directions for developing this
compound, including potential use of the animal
efficacy rule,» Cihlar said, referring to a regulatory mechanism under which the U.S. Food and Drug Administration may consider
efficacy findings from adequate and well - controlled animal
studies of a drug in cases where it is not feasible or ethical to conduct human trials.
A Phase 1/2 Open - label
Study of the Safety, Tolerability and
Efficacy of the Selective Inhibitor of Nuclear Export (SINE)
Compound KPT - 8602 in Patients with Relapsed / Refractory Cancer Indications
Among this class of derivatives,
compound 2 (AMD070, AnorMED) is particularly notable due to its significant anti-HIV
efficacy in human clinical
studies [86].
In addition, the knowledge must be imparted to scientists
studying the
efficacy of drugs on a variety of diseases that may be affected by
compounds in soy.
Future
studies will test and compare the
efficacy of imatinib and allosteric
compounds in mouse models of breast cancer.
The
study's original aim was to test the
compound more generally to determine its
efficacy and to see if cruciferous vegetables actually do inhibit the development of bladder cancer cells.
«Through this research, we can demonstrate that while other
compounds may reach peak
efficacy more quickly, REVOLUTION maintained greater than 90 percent
efficacy for a longer period than the other medications tested in the
study,» said J. Michael McFarland, DVM, DABVP, and group director of Companion Animal Veterinary Operations for Zoetis.
The
efficacy of cannabis and CBD
compounds as a treatment for pets is being
studied, but it has not been scientifically established, nor has a therapeutic dosage been determined.